| QUOTE |
| Joanne Rhoads, the physician who directs the FDA's Division of Scientific Investigations, says that view isn't realistic. ``What the FDA regulations require is not any gold standard for trials,'' Rhoads, 55, says. The agency doesn't have enough staff to aggressively monitor trials, she says, adding that FDA regulations are a bare minimum and much more oversight is needed. ``You cannot rely on the inspection process to get quality into the system,'' Rhoads says. ``I know many people find this not OK, but that's just the truth.'' |
| QUOTE |
| Polsgrove, 55, died during a trial for generic schizophrenia drug clozapine that was sponsored by Miami-based Ivax Corp., the largest U.S. maker of generic drugs. Fabre left Polsgrove in the care of John Rodriguez, who had no medical credentials, according to the FDA. Just six days before Polsgrove enrolled in the experiment, an FDA inspector visited Fabre's clinic and found that Rodriguez had screened subjects, performed physicals and conducted electrocardiograms. The inspector believed Fabre's false claim that Rodriguez was a licensed physician's assistant, Rhoads says. A call to the Texas Board of Medical Examiners would have revealed that Rodriguez was unlicensed. Rhoads says FDA inspectors don't normally verify medical licenses. ``On a routine inspection, it's not likely that they're going to dig because it takes a lot of work to do that,'' Rhoads says. |
| QUOTE |
| The FDA can investigate a trial site at any time. Rhoads says when inspectors review a test center, they follow a checklist. ``The bottom line is, the inspections by the FDA field investigators are done by people who are trained in investigation, but they don't always have a tremendous scientific or medical background,'' Rhoads says. ``They're basically doing an audit process.'' |